Edition:
United States

McKesson Corp (MCK.N)

MCK.N on New York Stock Exchange

109.19USD
18 Dec 2018
Change (% chg)

$-2.71 (-2.42%)
Prev Close
$111.90
Open
$113.13
Day's High
$113.29
Day's Low
$108.59
Volume
553,517
Avg. Vol
387,500
52-wk High
$178.86
52-wk Low
$108.59

Chart for

About

McKesson Corporation is a healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology company. The Company provides medicines, medical products and healthcare services by partnering with pharmaceutical manufacturers, providers, pharmacies, government... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $24,556.84
Shares Outstanding(Mil.): 195.38
Dividend: 0.39
Yield (%): 1.24

Financials

  MCK.N Industry Sector
P/E (TTM): -- 21.34 31.44
EPS (TTM): -7.99 -- --
ROI: -6.19 10.60 53.37
ROE: -15.99 11.89 60.82

McKesson cannot claw back funds owed to subsidiary in Orexigen bankruptcy - judge

Bankrupt obesity-drug maker Orexigen Therapeutics can keep $6.9 million it received from drug distributor McKesson Corp even though the former owes far more than that to a McKesson subsidiary, the judge overseeing the case ruled on Tuesday.

Nov 14 2018

McKesson's Change Healthcare hires IPO underwriters: sources

Change Healthcare LLC, a healthcare technology company majority-owned by U.S. drug wholesaler McKesson Corp , has hired underwriters for an initial public offering that could value it at as much as $12 billion, including debt, people familiar with the matter said on Wednesday.

Oct 03 2018

McKesson's Change Healthcare hires IPO underwriters -sources

Oct 3 Change Healthcare LLC, a healthcare technology company majority-owned by U.S. drug wholesaler McKesson Corp, has hired underwriters for an initial public offering that could value it at as much as $12 billion, including debt, people familiar with the matter said on Wednesday.

Oct 03 2018

Pharma's middlemen see shares suffer as challenges grow

NEW YORK, July 25 Uncertainty over potential actions to reduce prescription drug costs and competitive threats have taken a toll this year on shares of companies in the U.S. pharmaceutical supply chain. They get their chance to change investor sentiment with quarterly earnings reports in the coming days.

Jul 25 2018

Earnings vs. Estimates